# Avenue Therapeutics, Inc. (ATXI)

> Source: Nexqual · https://nexqual.com/ATXI · data as of 2026-10-23 20:00 UTC · cite as "Nexqual, Avenue Therapeutics, Inc. (ATXI), nexqual.com/ATXI" · informational, not investment advice.

**Price:** USD 0.39 (-4.75% on the day) · last close of Oct 23, 2026; US market closed, not a live price. Prev close 0.4 · day 0.39–0.39 · 52w 0.15–0.97 · market cap $1.3M · OID

## Key facts
- Analysts: None.
- Total return with dividends: 1Y -45.8% vs S&P 500 +13.4%; 5Y -100.0% vs S&P 500 +76.9%.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0K | $1.4M | — |
| Operating income | -$3.7M | -$8.0M | -$14.5M | -$11.3M | -$3.1M | -$2.9M |
| Net income | -$3.7M | -$3.6M | -$10.5M | -$11.7M | -$2.9M | -$2.8M |
| EPS (diluted) | -$247.50 | — | — | — | — | — |
| Operating margin | — | — | — | — | -219.6% | — |
| Net margin | — | — | — | — | -207.2% | — |
| Cash + short-term investments | $3.8M | $6.7M | $1.8M | $2.6M | $2.9M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 2.2x · Earnings yield -218.91%

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -45.8% | -100.0% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -45.9% | -81.5% |
| Volatility (annualized) | 206.8% | 149.6% |
| Max drawdown | -83.8% (Nov 2025→Feb 2026) | -100.0% (Nov 2021→Feb 2026) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 303.53 -1.39% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 89.27 -1.79% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.09 -0.35% · PRAX (Praxis Precision Medicines, Inc) USD 252.96 -2.30% · IONS (Ionis Pharmaceuticals, Inc.) USD 42.93 -2.23% · AXSM (Axsome Therapeutics, Inc.) USD 145.04 -7.07%

## More
Full page: https://nexqual.com/ATXI · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in ATXI's own 10-K filed 2026-03-30 (https://www.sec.gov/Archives/edgar/data/1644963/000143774926010359/atxi20251231_10k.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | AnnJi Pharmaceutical | "As a result of the Termination and Transfer Agreement with AnnJi and the disposition of Baergic, we have lost ownership and control of AJ201 and BAER‑101 (AXS‑17), which together had constituted two of our primary produc…" |
| Partner | Influence of Fortress Biotech | "Fortress transferred all its rights and obligations under the Tramadol License Agreement and the Manufacturing Agreement to us pursuant to an Asset Transfer Agreement, dated as of May 13, 2015." |
| Partner | Revogenex Ireland | "Pursuant to the Tramadol License Agreement described above, we have exclusive, worldwide commercialization rights to all Revogenex patents, including patent applications, divisionals, continuations, and continuations-in-…" |
| Partner | Baergic Bio | "As a result of the Termination and Transfer Agreement with AnnJi and the disposition of Baergic, we have lost ownership and control of AJ201 and BAER‑101 (AXS‑17), which together had constituted two of our primary produc…" |
| Partner | Fortress and InvaGen Pharmaceuticals | "We entered into a share repurchase agreement with InvaGen, which requires us to pay InvaGen seven and a half (7.5%) of the proceeds of future financings, as defined in the agreement, up to $4.0 million in aggregate." |

Other companies that name ATXI in their own reports (relationship from ATXI's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | Fortress Biotech, Inc. (FBIOP) | 10-K 2026-03-31 | "Our subsidiary and partner companies that are pursuing development and/or commercialization of biopharmaceutical products and product candidates are: Journey Medical Corporation (Nasdaq: DERM, "Journe…" |

## Company outlook (8-K filed 2024-11-14)

- "EX-99.1 2 ex_748191.htm EXHIBIT 99.1 ex_748191.htm Exhibit 99.1 Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - Topline data in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy anticipated around year-end 2024 Miami, FL – November 14, 2024 – Avenue Therapeutics, Inc."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2024-12-31) | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends 2024-12-31) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |